These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 17371318)

  • 1. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital.
    Antoniou C; Stefanaki I; Stratigos A; Avgerinou G; Stavropoulos P; Potouridou I; Polidorou D; Moustou AE; Kosmadaki M; Katsambas AD
    Br J Dermatol; 2007 Apr; 156 Suppl 2():12-6. PubMed ID: 17371318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice.
    Puig L; Roé E; García-Navarro X; Corella F; Alomar A
    Clin Exp Dermatol; 2009 Jun; 34(4):469-75. PubMed ID: 19077105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
    Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
    Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute.
    Ferrándiz C; Carrascosa JM
    Br J Dermatol; 2007 Apr; 156 Suppl 2():24-9. PubMed ID: 17371320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
    Papp KA; Miller B; Gordon KB; Caro I; Kwon P; Compton PG; Leonardi CL;
    J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S164-70. PubMed ID: 16488338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efalizumab in the treatment of chronic plaque psoriasis: experiences from the largest psoriasis treatment centre in Denmark.
    Kragballe K
    Br J Dermatol; 2007 Apr; 156 Suppl 2():7-11. PubMed ID: 17371317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efalizumab in the treatment of psoriasis.
    Gupta AK; Cherman AM
    J Cutan Med Surg; 2006; 10(2):57-68. PubMed ID: 17241576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
    JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
    Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
    N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience.
    Costanzo A; Peris K; Talamonti M; Di Cesare A; Fargnoli MC; Botti E; Chimenti S
    Br J Dermatol; 2007 Apr; 156 Suppl 2():17-23. PubMed ID: 17371319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efalizumab in routine use: a clinical experience.
    Selenko-Gebauer N; Karlhofer F; Stingl G
    Br J Dermatol; 2007 Apr; 156 Suppl 2():1-6. PubMed ID: 17371316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment.
    Bonnekoh B; Pommer AJ; Böckelmann R; Hofmeister H; Philipsen L; Gollnick H
    Skin Pharmacol Physiol; 2007; 20(5):237-52. PubMed ID: 17587888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].
    Ortonne JP; Shear N; Shumack S; Henninger E;
    BMC Dermatol; 2005 Dec; 5():13. PubMed ID: 16359548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efalizumab].
    Descamps V
    Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):666-78. PubMed ID: 17053736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
    Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
    Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis.
    Leonardi C; Menter A; Hamilton T; Caro I; Xing B; Gottlieb AB
    Br J Dermatol; 2008 May; 158(5):1107-16. PubMed ID: 18373710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy.
    Costanzo A; Talamonti M; Spallone G; Botti E; Chimenti MS; Papoutsaki M; Chimenti S
    Dermatology; 2009; 218(2):146-50. PubMed ID: 18971577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
    Leonardi CL; Papp KA; Gordon KB; Menter A; Feldman SR; Caro I; Walicke PA; Compton PG; Gottlieb AB;
    J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):425-33. PubMed ID: 15761420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.